Emergent BioSolutions Inc
F:ER4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Emergent BioSolutions Inc
F:ER4
|
US |
|
K
|
Knowit AB (publ)
XBER:KOW
|
SE |
|
C
|
Conrad Asia Energy Ltd
ASX:CRD
|
ID |
|
M
|
Microchip Technology Inc
XHAN:MCP
|
US |
|
S
|
Shenandoah Telecommunications Co
F:SH9
|
US |
|
Two Harbors Investment Corp
F:2H2
|
US |
|
Figeac Aero SARL
F:1F1
|
FR |
Emergent BioSolutions Inc
Emergent BioSolutions makes medical countermeasures and specialty products for public health, defense, and emergency response customers. Its core business includes vaccines, antibody-based products, and drug products used to treat or prevent serious biological and chemical threats, as well as devices and services tied to those products. It also sells certain products used in other medical settings, but the company is best known for supplying governments and health agencies that need hard-to-build defenses against rare but high-risk threats. The company earns money by developing these products itself, manufacturing them, and selling them under government contracts, commercial agreements, and product supply arrangements. A large part of its business comes from serving the U.S. government and other public-sector buyers that stockpile or deploy these medical countermeasures for national security and emergency preparedness. It also makes money from sales of some branded and licensed products in the broader healthcare market. What makes Emergent different is its role as a specialized supplier in a niche part of healthcare where reliability, regulatory know-how, and secure manufacturing matter more than broad consumer reach. Instead of selling everyday drugs to mass-market patients, it focuses on products that must be developed, approved, stored, and delivered for crisis situations. That makes it a company tied closely to government preparedness and public health infrastructure rather than a typical pharmaceutical maker.
Emergent BioSolutions makes medical countermeasures and specialty products for public health, defense, and emergency response customers. Its core business includes vaccines, antibody-based products, and drug products used to treat or prevent serious biological and chemical threats, as well as devices and services tied to those products. It also sells certain products used in other medical settings, but the company is best known for supplying governments and health agencies that need hard-to-build defenses against rare but high-risk threats.
The company earns money by developing these products itself, manufacturing them, and selling them under government contracts, commercial agreements, and product supply arrangements. A large part of its business comes from serving the U.S. government and other public-sector buyers that stockpile or deploy these medical countermeasures for national security and emergency preparedness. It also makes money from sales of some branded and licensed products in the broader healthcare market.
What makes Emergent different is its role as a specialized supplier in a niche part of healthcare where reliability, regulatory know-how, and secure manufacturing matter more than broad consumer reach. Instead of selling everyday drugs to mass-market patients, it focuses on products that must be developed, approved, stored, and delivered for crisis situations. That makes it a company tied closely to government preparedness and public health infrastructure rather than a typical pharmaceutical maker.
Beat: Emergent reported first-quarter revenue of $156 million, above the top end of guidance, and adjusted EBITDA of $36 million, also above internal expectations.
Outlook: Full-year revenue guidance was maintained at $720 million to $760 million, while adjusted EBITDA guidance was updated to $155 million to $175 million to reflect a change in how stock compensation is added back.
NARCAN: Management said the naloxone franchise should stay flat to slightly up for the year, supported by new product line extensions, seasonality, and continued demand in the U.S. and Canada.
International growth: The company highlighted stronger international MCM demand, with international sales making up 37% of MCM revenue in the quarter and carrying higher margins than U.S. business.
Balance sheet: Emergent said it reduced net debt by about 22% year over year, refinanced its term loan in April, and ended the quarter with $260 million of total liquidity.
Strategic push: Management framed 2026 as a pivotal year for the turnaround, with more investment in internal R&D, international expansion, and external product partnerships such as Substipharm and SAB Biotherapeutics.
